Mito-TEMPO

CAT: 0804-HY-112879-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-112879-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic with superoxide and alkyl radical scavenging properties[1].
CAS Number
[1334850-99-5]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Mitochondrial Metabolism; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Mito-TEMPO.html
Purity
99.19
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 60 mg/mL (ultrasonic)
Smiles
[O]N1C(C)(C)CC(NC(C[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=O)CC1(C)C.[Cl-]
Molecular Formula
C29H35ClN2O2P
Molecular Weight
510.03
Precautions
H302, H315, H319, H335
References & Citations
[1]Du K, et al. Mito-tempo protects against acute liver injury but induces limited secondary apoptosis during the late phase of acetaminophen hepatotoxicity. Arch Toxicol. 2018 Oct 15.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
ACS Nano. 2025 Mar 25;19 (11) :11029-11048.|Acta Pharm Sin B. 2022 Feb;12 (2) :759-773.|Acta Pharmacol Sin. 2024 Aug;45 (8) :1660-1672.|Acta Pharmacol Sin. 2025 Jul;46 (7) :1974-1989.|Adv Sci (Weinh) . 2023 Mar;10 (9) :e2207084.|Adv Sci (Weinh) . 2025 Sep 15:e07283.|Adv Sci (Weinh) . 2025 Sep 26:e05486.|Aging (Albany NY) . 2020 Jun 11;12 (11) :11116-11138.|Antioxidants (Basel) . 2022 Jul 26;11 (8) :1455.|Aquaculture. 2025 Feb 15.|Arch Biochem Biophys. 2024 Jul 17:110102.|Arch Oral Biol. 2023 Mar:147:105632.|Arthritis Res Ther. 2023 Jul 19;25 (1) :121.|Authorea. 2023 Aug 7.|Autophagy. 2024 Apr;20 (4) :752-768.|Basic Res Cardiol. 2022 Aug 23;117 (1) :40.|Biochem Biophys Rep. 2025 Jan 9:41:101909.|Biochem Biophys Res Commun. 2023 Nov 5:680:184-193.|Biochem Pharmacol. 2025 Apr 4:116932.|Biochim Biophys Acta Mol Basis Dis. 2023 Aug;1869 (6) :166740.|Biochim Biophys Acta Mol Basis Dis. 2025 Apr 23;1871 (6) :167866.|Biochim Biophys Acta Mol Basis Dis. 2025 Apr 26;1871 (6) :167874.|Biochim Biophys Acta Mol Cell Res. 2025 Dec;1872 (8) :120059.|Biol Pharm Bull. 2025;48 (11) :1741-1752.|Biol Trace Elem Res. 2024 Sep;202 (9) :4180-4190.|Biomaterials. 2025 Sep:320:123259.|Biomed Pharmacother. 2022 Sep:153:113280.|Biomol Biomed. 2025 Oct 29.|bioRxiv. 2025 Nov 11.|Biosci Biotechnol Biochem. 2024 May 8:zbae058.|Cell Calcium. 2025 Aug 26:132:103071.|Cell Commun Signal. 2023 May 25;21 (1) :123.|Cell Death Differ. 2024 Nov;31 (11) :1519-1533.|Cell Death Dis. 2020 May 5;11 (5) :319.|Cell Death Dis. 2025 Jul 1;16 (1) :482.|Cell Death Discov. 2023 Nov 18;9 (1) :419.|Cell Mol Life Sci. 2025 Jun 5;82 (1) :226.|Cell Prolif. 2023 Sep;56 (9) :e13442.|Cell Signal. 2022 May:93:110304.|Cell Signal. 2025 Apr 22:111829.|Chem Biol Interact. 2024 Dec 31:111368.|Chem Biol Interact. 2025 Jan 5:405:111269.|Clin Complement Med Pharmacol. 2024 May 21.|Clin Transl Med. 2024 Apr;14 (4) :e1653.|Clin Transl Med. 2025 Apr;15 (4) :e70289.|Clin Transl Med. 2025 Jun;15 (6) :e70385.|Dev Cell. 2025 Apr 18:S1534-5807 (25) 00206-0.|Dev Neurosci. 2022;44 (4-5) :309-319.|Diabetol Metab Syndr. 2025 Jul 16;17 (1) :267.|Ecotoxicol Environ Saf. 2024 Mar 15:273:116150.|Environ Int. 2023 Aug:178:108138.|Environ Pollut. 2024 May 15:349:123874.|Environ Sci Technol. 2025 Aug 5;59 (30) :15705-15719.|Eur J Pharmacol. 2024 Apr 15:969:176459.|Eur J Pharmacol. 2025 Oct 15:1005:178118.|FASEB J. 2022 Aug;36 (8) :e22475.|FASEB J. 2023 Jun;37 (6) :e22954.|FEBS Lett. 2021 Oct;595 (19) :2447-2462.|Fish Shellfish Immunol. 2024 Jan:144:109261.|Free Radic Biol Med. 2024 Aug 1:220:179-191.|Free Radic Biol Med. 2024 Feb 20:212:493-504.|Free Radic Biol Med. 2024 Jul 9:S0891-5849 (24) 00552-5.|Free Radic Biol Med. 2024 Nov 5:225:856-870.|Free Radic Biol Med. 2025 Feb 16:228:183-196.|Free Radic Biol Med. 2025 Jul:234:1-18.|Free Radic Biol Med. 2025 Jun 14:237:585-599.|Free Radic Biol Med. 2025 Jun:233:86-101.|Front Med. 2022 Jul 22:9:887062.|Front Oncol. 2022 May 18:12:874900.|Genes Dis. 2025 Sep 23.|Hepatol Commun. 2024 Mar 18;8 (4) :e0399.|Immunity. 2024 Jun 19:S1074-7613 (24) 00305-4.|Immunity. 2025 Apr 8;58 (4) :811-825.e7.|Int Immunopharmacol. 2024 Oct 29;143 (Pt 2) :113504.|Int Immunopharmacol. 2025 Aug 11:164:115325.|Int Immunopharmacol. 2025 May 30:160:114984.|Int Immunopharmacol. 2026 Jan 1;168 (Pt 1) :115862.|Int J Biol Macromol. 2025 Dec;334 (Pt 1) :149021.|Int J Biol Sci. 2022 Mar 6;18 (6) :2261-2276.|Int J Biol Sci. 2024 Apr 29;20 (7) :2658-2685.|Int J Biol Sci. 2024 Aug 19;20 (11) :4476-4495.|Int J Mol Med. 2025 Jun;55 (6) :96.|Int J Mol Sci. 2023 Mar 27;24 (7) :6309.|J Agric Food Chem. 2023 Aug 30;71 (34) :12645-12656.|J Agric Food Chem. 2023 Nov 1;71 (43) :16310-16322.|J Agric Food Chem. 2025 Apr 23;73 (16) :9906-9919.|J Biomed Sci. 2023 Nov 7;30 (1) :91.|J Cell Mol Med. 2025 Jul;29 (13) :e70613.|J Diabetes Investig. 2023 Jan;14 (1) :28-36.|J Ethnopharmacol. 2024 Jun 11:118455.|J Ethnopharmacol. 2025 Nov 28:358:120957.|J Exp Clin Cancer Res. 2025 Jul 4;44 (1) :193.|J Hazard Mater. 2022 Feb 15;424 (Pt A) :127268.|J Hazard Mater. 2023 Sep 5:457:131750.|J Hazard Mater. 2024 Apr 5:467:133719.|J Hazard Mater. 2024 Jun 7:475:134854.|J Hazard Mater. 2024 May 15:470:134142.|J Immunother Cancer. 2024 Nov 24;12 (11) :e009805.|J Inflamm Res. 2025 Aug 14:18:11095-11108.|J Proteome Res. 2025 Aug 1;24 (8) :4098-4113.|J Transl Med. 2025 Nov 10;23 (1) :1254.|Keimyung University. 2025.|Leukemia. 2023 Apr;37 (4) :765-775.|Life Sci. 2025 May 30:123780.|Mar Drugs. 2025 Mar 12;23 (3) :123.|Mol Biomed. 2025 Oct 2;6 (1) :75.|Mol Hum Reprod. 2020 Oct 1;26 (10) :773-783.|Mol Pain. 2025 Aug 28:17448069251377633.|Molecules. 2023 Jun 14;28 (12) :4770.|NanoImpact. 2025 Jun 15:39:100572.|Nat Commun. 2023 Feb 16;14 (1) :872.|Nat Commun. 2025 Aug 26;16 (1) :7954.|Nat Microbiol. 2025 Oct;10 (10) :2521-2536.|Oncogene. 2025 Sep 16:10.1038/s41388-025-03571-1.|OncoTargets and Therapy Dovepress. 2020 May 18;15:1093-1101.|Oral Dis. 2025 Feb;31 (2) :577-588.|Oxid Med Cell Longev. 2023 Feb 10:2023:6726654.|Oxid Med Cell Longev. 2023 Feb 17:2023:1708251.|Phytomedicine. 2024 Dec:135:156139.|Phytomedicine. 2024 Jul:129:155570.|Phytomedicine. 2024 Nov 14:136:156260.|Phytother Res. 2025 Feb;39 (2) :581-592.|Placenta. 2023 Nov:143:1-11.|PLoS One. 2020 Oct 1;15 (10) :e0239659.|PLoS Pathog. 2024 Nov 5;20 (11) :e1012614.|Redox Biol. 2020 Jul;34:101559.|Redox Biol. 2023 Feb:59:102587.|Redox Biol. 2023 Jun:62:102702.|Redox Biol. 2023 Sep:65:102828.|Redox Biol. 2024 Nov 20:78:103439.|Redox Biol. 2025 Sep:85:103750.|Redox Rep. 2024 Dec;29 (1) :2377870.|Redox Rep. 2025 Dec;30 (1) :2550412.|Res Sq. 2024 Jun 09.|Res Sq. 2024 Sep 22.|Research Square Preprint. 2022 May.|Research Square Preprint. 2024 Mar 19.|Sci Adv. 2025 Jul 18;11 (29) :eadw5228.|Sci Total Environ. 2023 Dec 20:905:166890.|Science. 2025 Mar 7;387 (6738) :eadq2509.|SSRN. 2025 Mar 20.|SSRN. 2025 Sep 17.|Theranostics. 2025 Jan 20;15 (6) :2360-2374.|Tissue Cell. 2025 Sep 18:98:103141.|Vet Sci. 2024 Dec 12;11 (12) :643.|Virus Res. 2023 Dec:338:199238.|Ecotoxicol Environ Saf. 2025 Apr 3:295:118139.

Related Products

CatalogName
HY-W001187-01Tempo
HY-W001187R-01Tempo (Standard)
HY-W001187STempo-d18
HY-151847-01N3-TEMPO
HY-D2295Mito-FerroGreen
HY-W002004-014-Amino-TEMPO
HY-162422-01Mito-DK
HY-168260CQ-Mito
HY-D1359-01Mito Red
HY-D1250-01Mito-TRFS

Alternative Products

CatalogName
MBS3844673-01Mito-TEMPO
9486-25Mito-TEMPO (hydrate)
A20224-25Mito-TEMPO 25mg
A20224-100Mito-TEMPO 100mg
A20224-50Mito-TEMPO 50mg
A20224-5Mito-TEMPO 5mg
A20224-10Mito-TEMPO 10mg
A20224-500Mito-TEMPO 500mg
A20224-10mM-DMito-TEMPO 10mM * 1mL in DMSO
TBI4100-5MGMito-TEMPO, Mitochondria targeted antioxidant

Popular Products